Skip to main content

We've updated our Privacy Policy. Questions? Email us any time at privacy@ground.news

SubscribeLogin
Published • loading... • Updated

Edgewise ups R&D spending as pharma firm focuses on cardiovascular pipeline

Summary by BizWest
Edgewise spent more on research and development as the Boulder firm moves from muscular-dystrophy drug candidates to cardiovascular therapies.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

BizWestBizWest

Edgewise ups R&D spending as pharma firm focuses on cardiovascular pipeline

Edgewise spent more on research and development as the Boulder firm moves from muscular-dystrophy drug candidates to cardiovascular therapies.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

BizWest broke the news on Thursday, August 6, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Boulder, Colorado icon

Boulder, Colorado

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal